This paper reframes the systemic benefits of GLP-1 receptor agonists through a pericyte-centered lens. While GLP-1 therapies are conventionally described in terms of endocrine and metabolic effects, this analysis integrates evidence across vascular biology, neuroprotection, renal physiology, adipose remodeling, and islet function to demonstrate that pericytes are the true mediators of GLP-1’s diverse clinical profile.
The paper synthesizes data on GLP-1 receptor expression in pericytes across multiple tissues (brain, kidney, pancreas, adipose, retina) and shows how GLP-1R activation stabilizes pericyte bioenergetics, nitric oxide coupling, barrier integrity, and immune gating. A structured mapping links pericyte functions to clinical outcomes, supported by a comparative table of organ systems.
By positioning GLP-1 agonists as prototype pericyte stabilizers, the work establishes a unifying systems-level framework that explains why these drugs deliver multi-organ protection. It also outlines predictive biomarkers and translational implications, providing a foundation for future research on pericyte-targeted therapies beyond diabetes and obesity.
The present analysis extends insights from Decoding TSRP: The Pericyte Connection, where pericytes were first positioned as the core terrain regulators destabilized by external perturbations, to the context of GLP-1 receptor therapy, and reframes the GLP-1 therapeutic profile through the lens of pericyte biology.